These are unique collaborations. We look at it as coalition for us to accelerate not only the development but the approval and commercialization of andexanet. These are collaborations where our colleagues from BMS/Pfizer, J&J/Bayer and Daiichi provide capital and funding for the development of andexanet.
They provide us some insight and input as to the best way to study andexanet with their compounds, but we retain 100% commercialization rights and decision-making around the compound, so that makes it very, very unique, that we pursue the collaborations this way.
These are designed to stay in effect for the development period, and then we'll make a determination in the future as to whether these collaborations continue through commercialization. But the good thing is, both andexanet and -- I'm not sure if I mentioned betrixaban -- both of those compounds, we can market them ourselves.
(unmet need and accelerated approval designated by FDA)
SMDC, named EC1456, which is specifically targeted to folate receptor-expressing tumors and produces (((curative activity in 100 percent of animals treated)))) under conditions that do not cause appreciable toxicity.
EC1456 is currently being evaluated in a Phase 1 trial in patients with advanced solid tumors
***A very important phase I trial for investors to watch. Good news and Merck will be buying Endocyte at a huge premium?
This study is currently recruiting participants.
Verified November 2013 by Endocyte
Dec 12, 2013
ENDOCYTE ENROLLS FIRST PATIENT IN PHASE 1 STUDY FOR THE SMALL MOLECULE DRUG CONJUGATE EC1456, A FOLATE-TARGETED TUBULYSIN CONJUGATE IN ADVANCED SOLID TUMORS
If max dosage shows potency against tumors that may lead to "cures"...
Another google worth reading
After two headline successes, companies rush to develop “smart bomb” cancer drugs.
By Megan Scudellari | November 1, 2012
Conjugates of the future
...Merck is also putting its money behind another ADC outlier—using a small molecule in place of a bulky antibody, which could more successfully target dense, solid tumors. Indiana–based Endocyte has constructed a drug conjugate of a potent chemotherapy drug bound to folate, a water-soluble B vitamin. Because folate is required for cell division, rapidly dividing cells like cancer cells often overexpress folate receptors. Impressive data on Endocyte’s lead candidate, vintafolide, from a phase II trial for drug-resistant ovarian cancer caught Merck’s attention, and the pharma company has agreed to pay up to a staggering $1 billion to advance the compound against various types of cancer.
Found Immunogen is trying their linker with folate targeting and seems to be having a lot of trouble simply getting through the dosage stage.
First impression, Endocyte has a huge lead in this area and I'm guessing it's linker technology
How effective is the linker in releasing the drug into the diseased cell?
VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES
United States Patent Application 20140058063 Kind Code: A1
Lots of info if you google the above. Possible uses range from cancer, to parasites, viruses, bacteria, arthritis.
In 2013 1,964,694 shares converted at 0.218 resulting in $428 thousand to the company. Another 4,232,508 to go.
Any new financing will be very interesting (if) they could get converts out of the way of investors. Financing likely to be unfriendly to current shareholders?
Somebody negotiated the Series A with a 0.28 conversion rate. Small companies can make some really stupid mistakes when it comes to desperation financing. Throw in the HUGE contract (huge for TPCS) discussed on CC that is losing millions yearly....
I'm guessing the string of good news on Mevion and GTAT are overwhelmed and more toxic financing is the only answer to be expected in refinancing.
Merck is probably more interested in the next generation folate receptor target drug than it is in the first generation SMDC now being tested in ovarian and NSCLC. Just look at the early review of the next generation SMDC:
"For the first time we are disclosing the preclinical data for Endocyte's folate-targeted tubulysin SMDC, named EC1456, which is specifically targeted to folate receptor-expressing tumors and produces curative activity in 100 percent of animals treated under conditions that do not cause appreciable toxicity. EC1456 was further confirmed to be highly active against folate receptor-positive tumors resistant to vintafolide, paclitaxel and cisplatin. EC1456 is currently being evaluated in a Phase 1 trial in patients with advanced solid tumors along with etarfolatide, which is Endocyte's companion imaging agent for anatomically assessing tumor-associated folate receptor expression in real time
Endocyte wanted fast cash, $100zm in the bank via new stock to ward off a too aggressive Merck. As the EC-1456 phase one trial has huge potential to be a very important drug. (Just my guess)
Biotechs in general, A few of the buyouts have not produced sales expected. Wall Street pumps the good, the bad and the ugly.
Look at the market cap of PCRX. Talk to doctors who have tried it and the sales figures that give you and idea of what sales figures will ever look like. Disillusioned biotech investors are throwing out the good the bad and the ugly. Looking for babies in that bathwater and hope to make some long term investments. A quick bounce that would hold their prices is not what I'm expecting, yet. Gonna have to think long term and hold on to those babies in the bathwater.
Anyone have any idea what would signal a real bottom in this sector?
December 31, 2009, each share of Series A Convertible Preferred Stock was convertible into 1.3072 shares
December 31, 2013 5,532,735 common shares, respectively, underlying the Series A Convertible Preferred Stock.
The converts must be playing hell with the refi effort.
at December 31, 2009, each share of Series A Convertible Preferred Stock was convertible into 1.3072 shares of common stock, with an effective conversion price of $0.218. Based on the current conversion ratio, as of December 31, 2013 and March 31, 2013, there were 5,532,735 and 7,232,735 common shares, respectively, underlying the Series A Convertible Preferred Stock.
((conversion price of $0.218))
During the nine months ended December 31, 2013 and fiscal 2013, there were 1,300,490 and 1,502,984 shares of Series A Convertible Preferred Stock converted into 1,700,000 and 1,964,694 shares of common stock. At December 31, 2013 and March 31, 2013, we had 4,232,508 and 5,532,998 shares, respectively, of Series A Convertible Preferred Stock outstanding.
Looks like the demand from the customer side is aligning for a strong 2015 as management has been saying. The terms will only get better if TechPrecision can bridge financing until a later date?
GLTA, I'm guessing wildly as we seem to be passing the most recent deadline.
Siga is slashing staff and trying to partner ongoing programs like lasso fever.
PharmAthene is anxiously awaiting final rulings from Delaware. The CC explained the Sparvax trial hold was due to the fact that the FDA wanted new batches of Sparvax to be used in further trials. Also said that trials for Sparvax are looking good.
GLTA, added at 1.81 & hope for lower entries.
I'm guessing there are parties that would like to shake out momo type traders and pick up as many shares as possible at lower prices. The shady way to do it is aim right at the small guys and try to spook momo sellers to start a panic selling by real investors. Hope all invetors take a second look at the known buda data. GLTA
Again, Wall Street?
Luckily they were early arrivers to the buda area and have lucked into to some valuable properties. Hopefully their understanding of the buda allows for the best returns they continue to invest in the area.
Someone has come on the board today to bash US Energy. I would welcome any actual data they would like to share in helping others decide on their investment.
Biotech Mutual Funds are selling what they can sell, even the best. Hope the small investors are able to hold on for the long term gains. Would be glad to lower and lower. Gut Check feels like the bottom. Don't expect to see the pump and dump trash to raise from these lower levels.
Time to pick up shares of the good and wait for long term gains.